RT @SaskiaPopescu: Comparative study of four SARS-CoV-2 Nucleic Acid Amplification Test (NAAT) platforms demonstrates that ID NOW performan…
RT @SaskiaPopescu: Comparative study of four SARS-CoV-2 Nucleic Acid Amplification Test (NAAT) platforms demonstrates that ID NOW performan…
ID NOW can potentially be helpful in some specific situations - but let’s not forget, the devil is in the details on how this is implemented @fordnation it is not a panacea
RT @SaskiaPopescu: Comparative study of four SARS-CoV-2 Nucleic Acid Amplification Test (NAAT) platforms demonstrates that ID NOW performan…
"ID NOW performance stood out as significantly worse than the other 3 assays despitedemonstrating comparable analytic sensitivity" *sigh* #Theranos2 #COVID19
RT @SaskiaPopescu: Comparative study of four SARS-CoV-2 Nucleic Acid Amplification Test (NAAT) platforms demonstrates that ID NOW performan…
RT @SaskiaPopescu: Comparative study of four SARS-CoV-2 Nucleic Acid Amplification Test (NAAT) platforms demonstrates that ID NOW performan…
RT @SaskiaPopescu: Comparative study of four SARS-CoV-2 Nucleic Acid Amplification Test (NAAT) platforms demonstrates that ID NOW performan…
RT @SaskiaPopescu: Comparative study of four SARS-CoV-2 Nucleic Acid Amplification Test (NAAT) platforms demonstrates that ID NOW performan…
I cannot stress enough how important independent objective evaluations of each testing system is required to fully appreciate the context in which it could or shouldn’t be used. ❤️medical microbiology
RT @SaskiaPopescu: Comparative study of four SARS-CoV-2 Nucleic Acid Amplification Test (NAAT) platforms demonstrates that ID NOW performan…
RT @SaskiaPopescu: Comparative study of four SARS-CoV-2 Nucleic Acid Amplification Test (NAAT) platforms demonstrates that ID NOW performan…
A VERY important warning that the Abbott ID Now needs to be applied appropriately and has some serious limitations
@DataDrivenMD @kaitlancollins Another note: "ID NOW performance stood out as significantly worse than the other 3 assays despite demonstrating comparable analytic sensitivity." https://t.co/8dXLRqKOWI
Comparative study of four SARS-CoV-2 Nucleic Acid Amplification Test (NAAT) platforms demonstrates that ID NOW performance is impaired substantially by patient and specimen type - ScienceDirect https://t.co/RCkbWERBMg
Canada purchased 8M of this
Comparative study of four SARS-CoV-2 NAATs (... https://t.co/9vuoGN3FP1 The @AbbottNews ID NOW diagnostic test for #SARSCoV2 RNA performed significantly worse than similar tests, particularly in samples with low viral load and in nasal swab samples (vs NP